Simon N Waddington

List of Publications by Year
in descending order

184	8,112	50276	58581
papers	citations	46 h-index	82 g-index

198	198	198	10284
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rapid and inexpensive purification of adenovirus vectors using an optimised aqueous two-phase technology. Journal of Virological Methods, 2022, 299, 114305.	2.1	4
2	HIV- 1 lentivirus tethering to the genome is associated with transcription factor binding sites found in genes that favour virus survival. Gene Therapy, 2022, 29, 720-729.	4.5	2
3	Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translation. Molecular Therapy - Methods and Clinical Development, 2021, 20, 357-365.	4.1	2
4	Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development. Biomolecules, 2021, 11, 611.	4.0	27
5	Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism. Science Translational Medicine, 2021, 13, .	12.4	25
6	In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications. Viruses, 2021, 13, 1483.	3.3	4
7	Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. Molecular Therapy - Methods and Clinical Development, 2021, 23, 135-146.	4.1	21
8	Beclinâ€1â€mediated activation of autophagy improves proximal and distal urea cycle disorders. EMBO Molecular Medicine, 2021, 13, e13158.	6.9	16
9	Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload. Cell Death and Differentiation, 2020, 27, 1588-1603.	11.2	24
10	Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes. Human Molecular Genetics, 2020, 29, 1933-1949.	2.9	24
11	Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials: iFeTiS Consensus Statement. Molecular Therapy, 2020, 28, 2316-2319.	8.2	18
12	Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors. Scientific Reports, 2020, 10, 2121.	3.3	3
13	Cervical Gene Delivery of the Antimicrobial Peptide, Human Î²-Defensin (HBD)-3, in a Mouse Model of Ascending Infection-Related Preterm Birth. Frontiers in Immunology, 2020, 11, 106.	4.8	19
14	Impaired folate 1-carbon metabolism causes formate-preventable hydrocephalus in glycine decarboxylaseâ€“deficient mice. Journal of Clinical Investigation, 2020, 130, 1446-1452.	8.2	16
15	Continual Conscious Bioluminescent Imaging in Freely Moving Mice. Methods in Molecular Biology, 2020, 2081, 161-175.	0.9	1
16	Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort. Human Gene Therapy, 2019, 30, 79-87.	2.7	51
17	In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI Techniques. Scientific Reports, 2019, 9, 11592.	3.3	15
18	Fetal gene therapy for neurodegenerative lysosomal storage diseases. Journal of Inherited Metabolic Disease, 2019, 42, 391-393.	3.6	2

#	Article	IF	Citations
19	In Utero Gene Therapy Consensus Statement from the IFeTIS. Molecular Therapy, 2019, 27, 705-707.	8.2	32
20	Urea Cycle Related Amino Acids Measured in Dried Bloodspots Enable Long-Term In Vivo Monitoring and Therapeutic Adjustment. Metabolites, 2019, 9, 275.	2.9	4
21	Modifying inter-cistronic sequence significantly enhances IRES dependent second gene expression in bicistronic vector: Construction of optimised cassette for gene therapy of familial hypercholesterolemia. Non-coding RNA Research, 2019, 4, 1-14.	4.6	16
22	Production of lentiviral vectors using novel, enzymatically produced, linear DNA. Gene Therapy, 2019, 26, 86-92.	4.5	22
23	Therapeutic expression of human clotting factors IX and Ã— following adenoâ€associated viral vectorâ€mediated intrauterine gene transfer in earlyâ€gestation fetal macaques. FASEB Journal, 2019, 33, 3954-3967.	0.5	21
24	Progesterone, the maternal immune system and the onset of parturition in the mouseâ€. Biology of Reproduction, 2018, 98, 376-395.	2.7	33
25	High-efficiency transduction of spinal cord motor neurons by intrauterine delivery of integration-deficient lentiviral vectors. Journal of Controlled Release, 2018, 273, 99-107.	9.9	15
26	NF-Î²B Activity Initiates Human ESC-Derived Neural Progenitor Cell Differentiation by Inducing a Metabolic Maturation Program. Stem Cell Reports, 2018, 10, 1766-1781.	4.8	23
27	A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe Î²-thalassemia in a HbbTh3/+ murine model. Experimental Hematology, 2018, 62, 45-55.	0.4	10
28	Enhancement of mouse hematopoietic stem/progenitor cell function via transient gene delivery using integration-deficient lentiviral vectors. Experimental Hematology, 2018, 57, 21-29.	0.4	6
29	Dependency modelling for inconsistency management in Digital Preservation â€“ The PERICLES approach. Information Systems Frontiers, 2018, 20, 7-19.	6.4	2
30	Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer. Nature Communications, 2018, 9, 3505.	12.8	34
31	A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. Brain, 2018, 141, 2014-2031.	7.6	80
32	Fetal gene therapy for neurodegenerative disease of infants. Nature Medicine, 2018, 24, 1317-1323.	30.7	117
33	Ascending Vaginal Infection Using Bioluminescent Bacteria Evokes Intrauterine Inflammation, Preterm Birth, and Neonatal Brain Injury in Pregnant Mice. American Journal of Pathology, 2018, 188, 2164-2176.	3.8	52
34	Foamy Virus Vectors Transduce Visceral Organs and Hippocampal Structures following InÂVivo Delivery to Neonatal Mice. Molecular Therapy - Nucleic Acids, 2018, 12, 626-634.	5.1	7
35	AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemannâ€“Pick type C1 disease. Human Molecular Genetics, 2018, 27, 3079-3098.	2.9	51
36	Vps33b is crucial for structural and functional hepatocyte polarity. Journal of Hepatology, 2017, 66, 1001-1011.	3.7	51

#	Article	IF	Citations
37	Delivering efficient liver-directed AAV-mediated gene therapy. Gene Therapy, 2017, 24, 263-264.	4.5	11
38	Longitudinal in vivo bioimaging of hepatocyte transcription factor activity following cholestatic liver injury in mice. Scientific Reports, 2017, 7, 41874.	3.3	9
39	Expanding the phenotype in argininosuccinic aciduria: need for new therapies. Journal of Inherited Metabolic Disease, 2017, 40, 357-368.	3.6	55
40	In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model. Molecular Therapy, 2017, 25, 1843-1853.	8.2	30
41	Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy. Molecular Therapy, 2017, 25, 1790-1804.	8.2	32
42	Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. Journal of Inherited Metabolic Disease, 2017, 40, 497-517.	3.6	89
43	Lentiviral vectors can be used for full-length dystrophin gene therapy. Scientific Reports, 2017, 7, 79.	3.3	41
44	Lentiviral vectors can be used for full-length dystrophin gene therapy. Scientific Reports, 2017, 7, 44775.	3.3	29
45	The power of bioluminescence imaging in understanding host-pathogen interactions. Methods, 2017, 127, 69-78.	3.8	15
46	Bioluminescence Monitoring of Promoter Activity In Vitro and In Vivo. Methods in Molecular Biology, 2017, 1651, 49-64.	0.9	3
47	Continual conscious bioluminescent imaging in freely moving somatotransgenic mice. Scientific Reports, 2017, 7, 6374.	3.3	14
48	Haemophilia B Curative FIX Production from a Low Dose UCOE-based Lentiviral Vector Following Hepatic Pre-natal Delivery. Current Gene Therapy, 2016, 16, 231-241.	2.0	2
49	An ontology supporting planning, analysis, and simulation of evolving digital ecosystems. , 2016, , .		2
50	256. A Novel Rationally Designed AAV Capsid Yields a Potent Neurotropic Gene Therapy Vector. Molecular Therapy, 2016, 24, S101.	8.2	0
51	609. Transduction of the Central Nervous System with the LTR1 Lentiviral Backbone. Molecular Therapy, 2016, 24, S241.	8.2	0
52	305. Generation of Light-Producing, Somatic-Transgenic Mice Using Lentivirus and Adeno-Associated Virus Vectors. Molecular Therapy, 2016, 24, S123.	8.2	0
53	437. A Light-Producing Model of Infection-Related Preterm Birth. Molecular Therapy, 2016, 24, S173.	8.2	0
54	Regulation of post-Golgi LH3 trafficking is essential for collagen homeostasis. Nature Communications, 2016, 7, 12111.	12.8	54

#	Article	IF	Citations
55	Proofâ€ofâ€concept: neonatal intravenous injection of adenoâ€associated virus vectors results in successful transduction of myenteric and submucosal neurons in the mouse small and large intestine. Neurogastroenterology and Motility, 2016, 28, 299-305.	3.0	23
56	Flexible polyurethane foams formulated with polyols derived from waste carbon dioxide. Journal of Applied Polymer Science, 2016, 133, .	2.6	38
57	The Local and Systemic Immune Response to Intrauterine LPS in the Prepartum Mouse. Biology of Reproduction, 2016, 95, 125-125.	2.7	35
58	NRF2 Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell Reprogramming. Cell Reports, 2016, 14, 1883-1891.	6.4	132
59	Modeling hormonal and inflammatory contributions to preterm and term labor using uterine temporal transcriptomics. BMC Medicine, 2016, 14, 86.	5.5	63
60	Gene Therapy with Adeno-associated Virus for Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 234-236.	5.6	6
61	A Broad Overview and Review of CRISPR-Cas Technology and Stem Cells. Current Stem Cell Reports, 2016, 2, 9-20.	1.6	33
62	134. Generation of Light-Emitting Somatic-Transgenic Mice for Disease Modelling of Hypoxic Ischaemic Encephalopathy. Molecular Therapy, 2015, 23, S55.	8.2	0
63	181. Real-Time Monitoring of Transcription Factor Activity Using In Vitro and In Vivo Models of Cholestasis. Molecular Therapy, 2015, 23, S72.	8.2	0
64	380. Use of Somatotransgenic Bioimaging as a Platform for Studying NFκB Pathway in a Tissue-Specific Manner in Two Mouse Models of Inflammation: Rheumatoid Arthritis and Contact Dermatitis. Molecular Therapy, 2015, 23, S151.	8.2	0
65	529. Novel LTR-1 Lentiviral Vectors Are Fully Functional Following the Removal of HIV-1 Gag-RRE Sequences. Molecular Therapy, 2015, 23, S212.	8.2	1
66	Evidence for Contribution of CD4+CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery. Journal of Immunology Research, 2015, 2015, 1-6.	2.2	13
67	Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates. FASEB Journal, 2015, 29, 3876-3888.	0.5	31
68	In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters. Scientific Reports, 2015, 5, 11842.	3.3	41
69	Specific inhibition of c-Jun N-terminal kinase delays preterm labour and reduces mortality. Reproduction, 2015, 150, 269-277.	2.6	21
70	Specific Lipopolysaccharide Serotypes Induce Differential Maternal and Neonatal Inflammatory Responses in a Murine Model of Preterm Labor. American Journal of Pathology, 2015, 185, 2390-2401.	3.8	67
71	Designing for Inconsistency â€“ The Dependency-Based PERICLES Approach. Communications in Computer and Information Science, 2015, , 458-467.	0.5	3
72	On the Preservation of Evolving Digital Content â€“ The Continuum Approach and Relevant Metadata Models. Communications in Computer and Information Science, 2015, , 15-26.	0.5	1

#	Article	IF	Citations
73	Regionally-Specified Second Trimester Fetal Neural Stem Cells Reveals Differential Neurogenic Programming. PLoS ONE, 2014, 9, e105985.	2.5	5
74	Perinatal systemic gene delivery using adeno-associated viral vectors. Frontiers in Molecular Neuroscience, 2014, 7, 89.	2.9	18
75	Hyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy. Molecular Therapy, 2014, 22, 1614-1624.	8.2	48
76	Transduction of Fetal Mice With a Feline Lentiviral Vector Induces Liver Tumors Which Exhibit an E2F Activation Signature. Molecular Therapy, 2014, 22, 59-68.	8.2	17
77	Cloud computing in e-Science: research challenges andÂopportunities. Journal of Supercomputing, 2014, 70, 408-464.	3.6	34
78	Activator protein 1 is a key terminal mediator of inflammationâ€induced preterm labor in mice. FASEB Journal, 2014, 28, 2358-2368.	0.5	91
79	Harmonising Research Reporting in the UK â€“ Experiences and Outputs from UKRISS. Procedia Computer Science, 2014, 33, 207-214.	2.0	4
80	The Human Desmin Promoter Drives Robust Gene Expression for Skeletal Muscle Stem Cell-Mediated Gene Therapy. Current Gene Therapy, 2014, 14, 276-288.	2.0	9
81	Cloud repositories for research data â€“ addressing the needs of researchers. Journal of Cloud Computing: Advances, Systems and Applications, 2013, 2, 13.	3.9	4
82	Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Diseaseâ€”Links to Parkinsonâ€™s Disease. Cell Metabolism, 2013, 17, 941-953.	16.2	277
83	Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes. Journal of Inherited Metabolic Disease, 2013, 36, 869-872.	3.6	28
84	Î²-Glucosidase 2 (GBA2) Activity and Imino Sugar Pharmacology. Journal of Biological Chemistry, 2013, 288, 26052-26066.	3.4	69
85	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 2013, 121, 3335-3344.	1.4	236
86	Exon Skipping of Hepatic APOB Pre-mRNA With Splice-switching Oligonucleotides Reduces LDL Cholesterol In Vivo. Molecular Therapy, 2013, 21, 602-609.	8.2	26
87	The Fetal Mouse Is a Sensitive Genotoxicity Model That Exposes Lentiviral-associated Mutagenesis Resulting in Liver Oncogenesis. Molecular Therapy, 2013, 21, 324-337.	8.2	21
88	Feasibility Study Into the Reporting of Research Information at a National Level Within the UK Higher Education Sector. New Review of Information Networking, 2013, 18, 74-105.	0.5	3
89	Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Therapy, 2013, 20, 69-83.	4.5	54
90	Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy, 2013, 20, 1158-1164.	4.5	25

#	Article	IF	Citations
91	AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. Blood, 2012, 119, 957-966.	1.4	44
92	Identification of Jagged1 as a novel ligand for CD46: An interaction required for normal induction and regulation of human TH1 responses. Immunobiology, 2012, 217, 1176.	1.9	0
93	The novel Jagged1/CD46 interaction: A prime target for immune modulation by viruses?. Immunobiology, 2012, 217, 1210-1211.	1.9	1
94	The CD46-Jagged1 interaction is critical for human TH1 immunity. Nature Immunology, 2012, 13, 1213-1221.	14.5	163
95	The Concept of Prenatal Gene Therapy. , 2012, 891, 1-7.		3
96	Candidate Diseases for Prenatal Gene Therapy. , 2012, 891, 9-39.		16
97	Vector Systems for Prenatal Gene Therapy: Choosing Vectors for Different Applications. Methods in Molecular Biology, 2012, 891, 41-53.	0.9	4
98	Choice of Surrogate and Physiological Markers for Prenatal Gene Therapy. , 2012, 891, 273-290.		1
99	The case for intrauterine gene therapy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 697-709.	2.8	15
100	In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression. Gene Therapy, 2012, 19, 936-946.	4.5	31
101	Monitoring for Potential Adverse Effects of Prenatal Gene Therapy: Use of Large Animal Models with Relevance to Human Application. , 2012, 891, 291-328.		5
102	Animal Models for Prenatal Gene Therapy: Rodent Models for Prenatal Gene Therapy. , 2012, 891, 201-218.		4
103	Monitoring for Potential Adverse Effects of Prenatal Gene Therapy: Mouse Models for Developmental Aberrations and Inadvertent Germ Line Transmission. , 2012, 891, 329-340.		0
104	Fetal gene therapy: recent advances and current challenges. Expert Opinion on Biological Therapy, 2011, 11, 1257-1271.	3.1	19
105	Perinatal gene delivery to the CNS. Therapeutic Delivery, 2011, 2, 483-491.	2.2	8
106	Perinatal Gene Transfer to the Liver. Current Pharmaceutical Design, 2011, 17, 2528-2541.	1.9	18
107	Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood, 2011, 117, 798-807.	1.4	163
108	Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. Journal of Molecular Medicine, 2011, 89, 515-529.	3.9	60

#	Article	IF	Citations
109	Organ targeted prenatal gene therapyâ€"how far are we?. Prenatal Diagnosis, 2011, 31, 720-734.	2.3	17
110	Stable Human FIX Expression After 0.9G Intrauterine Gene Transfer of Self-complementary Adeno-associated Viral Vector 5 and 8 in Macaques. Molecular Therapy, 2011, 19, 1950-1960.	8.2	66
111	Recombinant Adeno-Associated Virus-Mediated In Utero Gene Transfer Gives Therapeutic Transgene Expression in the Sheep. Human Gene Therapy, 2011, 22, 419-426.	2.7	44
112	Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins. Molecular Therapy, 2011, 19, 876-885.	8.2	280
113	Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB Journal, 2011, 25, 3505-3518.	0.5	84
114	Recent advances in fetal gene therapy. Therapeutic Delivery, 2011, 2, 461-469.	2.2	12
115	Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood, 2010, 116, 2656-2664.	1.4	96
116	Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood, 2010, 116, 3645-3652.	1.4	32
117	Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis. Biochemical Society Transactions, 2010, 38, 1484-1488.	3.4	30
118	In utero gene transfer to the mouse nervous system. Biochemical Society Transactions, 2010, 38, 1489-1493.	3.4	12
119	Activation and deactivation of periventricular white matter phagocytes during postnatal mouse development. Glia, 2010, 58, 11-28.	4.9	95
120	LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. International Archive of Medicine, 2010, 3, 36.	1.2	42
121	Neonatal Gene Therapy of Glycogen Storage Disease Type Ia Using a Feline Immunodeficiency Virusâ€"based Vector. Molecular Therapy, 2010, 18, 1592-1598.	8.2	23
122	Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1333-1339.	2.4	70
123	Desmin-regulated Lentiviral Vectors for Skeletal Muscle Gene Transfer. Molecular Therapy, 2010, 18, 601-608.	8.2	30
124	Gene Delivery of a Mutant TGFÎ²3 Reduces Markers of Scar Tissue Formation After Cutaneous Wounding. Molecular Therapy, 2010, 18, 2104-2111.	8.2	29
125	The differentiation and engraftment potential of mouse hematopoietic stem cells is maintained after bio-electrospray. Analyst, The, 2010, 135, 157-164.	3.5	41
126	Assessing the Potential of Perinatal Gene Transfer Using Congenital Factor VII Deficiency as a Model System. Blood, 2010, 116, 247-247.	1.4	1

#	Article	IF	Citations
127	Stable High Level Coagulation Factor VIII Expression In Vivo Following Gene Transfer Using a Novel Expression Cassette Encoding a More Potent FVIII Variant. Blood, 2010, 116, 250-250.	1.4	4
128	Erratum to â€œInfluence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectorsâ€• Molecular Therapy, 2009, 17, 1830.	8.2	0
129	Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer. Journal of Virology, 2009, 83, 479-483.	3.4	72
130	Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype. Cell Cycle, 2009, 8, 1069-1079.	2.6	71
131	Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors. Molecular Therapy, 2009, 17, 1683-1691.	8.2	41
132	The Cyclopentenone 15-Deoxy-Î”12,14-Prostaglandin J2 Delays Lipopolysaccharide-Induced Preterm Delivery and Reduces Mortality in the Newborn Mouse. Endocrinology, 2009, 150, 699-706.	2.8	73
133	Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Therapy, 2009, 16, 509-520.	4.5	89
134	Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 2009, 114, 965-971.	1.4	158
135	Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Therapy, 2008, 15, 1593-1605.	4.5	91
136	Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression. Gene Therapy, 2008, 15, 1167-1175.	4.5	49
137	Genetic aspects and research development in haemostasis. Haemophilia, 2008, 14, 113-118.	2.1	3
138	Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer. Cell, 2008, 132, 397-409.	28.9	573
139	Luciferin Detection After Intranasal Vector Delivery Is Improved by Intranasal Rather Than Intraperitoneal Luciferin Administration. Human Gene Therapy, 2008, 19, 1050-1056.	2.7	34
140	Intra-amniotic Delivery of CFTR-expressing Adenovirus Does Not Reverse Cystic Fibrosis Phenotype in Inbred CFTR-knockout Mice. Molecular Therapy, 2008, 16, 819-824.	8.2	31
141	Two-Level Automatic Adaptation of a Distributed User Profile for Personalized News Content Delivery. International Journal of Digital Multimedia Broadcasting, 2008, 2008, 1-21.	0.6	12
142	Luciferin detection after intra-nasal vector delivery is improved by intra-nasal rather than intra-peritoneal luciferin administration.. Human Gene Therapy, 2008, .	2.7	0
143	Distributed User Modeling for Personalized News Delivery in Mobile Devices. , 2007, , .		2
144	Targeting of Adenovirus Serotype 5 (Ad5) and 5/47 Pseudotyped Vectors In Vivo: Fundamental Involvement of Coagulation Factors and Redundancy of CAR Binding by Ad5. Journal of Virology, 2007, 81, 9568-9571.	3.4	70

#	Article	IF	Citations
145	Influence of Coagulation Factor Zymogens on the Infectivity of Adenoviruses Pseudotyped with Fibers from Subgroup D. Journal of Virology, 2007, 81, 3627-3631.	3.4	62
146	Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors. Molecular Therapy, 2007, 15, 1947-1954.	8.2	165
147	Widespread Distribution and Muscle Differentiation of Human Fetal Mesenchymal Stem Cells After Intrauterine Transplantation in Dystrophic mdx Mouse. Stem Cells, 2007, 25, 875-884.	3.2	118
148	The Influence of Blood on In Vivo Adenovirus Bio-distribution and Transduction. Molecular Therapy, 2007, 15, 1410-1416.	8.2	62
149	Delivery and long-term expression of a 135 kbLDLR genomic DNA locusin vivo by hydrodynamic tail vein injection. Journal of Gene Medicine, 2007, 9, 488-497.	2.8	45
150	Fetal gene transfer. Current Opinion in Molecular Therapeutics, 2007, 9, 432-8.	2.8	16
151	Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 2006, 108, 2554-2561.	1.4	256
152	Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Therapy, 2006, 13, 117-126.	4.5	54
153	Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease. Gene Therapy, 2006, 13, 1665-1676.	4.5	32
154	Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006, 107, 2653-2661.	1.4	366
155	827. Oncogenesis Following Delivery of Lentiviral Vectors to Fetal and Neonatal Mice. Molecular Therapy, 2006, 13, S320.	8.2	0
156	458. Development of Non-Integrating and Site- Specifically Integrating Lentiviral Vectors. Molecular Therapy, 2006, 13, S177.	8.2	0
157	376. Hepatic Tropism of Adenoviral Type 5 Vectors Can Be Mediated by Multiple Coagulation Factors. Molecular Therapy, 2006, 13, S143.	8.2	1
158	Clinically Applicable Procedure for Gene Delivery to Fetal Gut by Ultrasound-Guided Gastric Injection: Toward Prenatal Prevention of Early-Onset Intestinal Diseases. Human Gene Therapy, 2006, 17, 767-779.	2.7	30
159	Targeting the respiratory muscles of fetal sheep for prenatal gene therapy for Duchenne muscular dystrophy. American Journal of Obstetrics and Gynecology, 2005, 193, 1105-1109.	1.3	19
160	Complement inhibition rescued mice allowing observation of transgene expression following intraportal delivery of baculovirus in mice. Journal of Gene Medicine, 2005, 7, 325-333.	2.8	41
161	No evidence for germ-line transmission following prenatal and early postnatal AAV-mediated gene delivery. Journal of Gene Medicine, 2005, 7, 630-637.	2.8	18
162	Gene Therapy Progress and Prospects: Fetal gene therapy â€“ first proofs of concept â€“ some adverse effects. Gene Therapy, 2005, 12, 1601-1607.	4.5	49

#	Article	IF	Citations
163	Factors Influencing Adenovirus-Mediated Airway Transduction in Fetal Mice. Molecular Therapy, 2005, 12, 484-492.	8.2	38
164	In Utero gene therapy: current challenges and perspectives. Molecular Therapy, 2005, 11, 661-676.	8.2	40
165	Oncogenesis Following Delivery of a Nonprimate Lentiviral Gene Therapy Vector to Fetal and Neonatal Mice. Molecular Therapy, 2005, 12, 763-771.	8.2	224
166	Widespread and efficient marker gene expression in the airway epithelia of fetal sheep after minimally invasive tracheal application of recombinant adenovirus in utero. Gene Therapy, 2004, 11, 70-78.	4.5	60
167	Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus. Gene Therapy, 2004, 11, 599-608.	4.5	17
168	Highly efficient EIAV-mediated in utero gene transfer and expression in the major muscle groups affected by Duchenne muscular dystrophy. Gene Therapy, 2004, 11, 1117-1125.	4.5	46
169	Fetal and neonatal gene therapy: benefits and pitfalls. Gene Therapy, 2004, 11, S92-S97.	4.5	42
170	Targeting the fetal respiratory muscles for prenatal gene therapy for duchenne muscular dystrophy. American Journal of Obstetrics and Gynecology, 2004, 191, S22.	1.3	0
171	Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood, 2004, 104, 2714-2721.	1.4	132
172	The Hopes and Fears of In Utero Gene Therapy for Genetic Diseaseâ€"A Review. Placenta, 2003, 24, S114-S121.	1.5	27
173	Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. Gene Therapy, 2003, 10, 1234-1240.	4.5	73
174	Ultrasound-Guided Percutaneous Delivery of Adenoviral Vectors Encoding theÎ²-Galactosidase and Human Factor IX Genes to Early Gestation Fetal SheepIn Utero. Human Gene Therapy, 2003, 14, 353-364.	2.7	66
175	In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood, 2003, 101, 1359-1366.	1.4	109
176	Sustained delivery of therapeutic concentrations of human clotting factor IX - a comparison of adenoviral and AAV vectors administeredin utero. Journal of Gene Medicine, 2002, 4, 46-53.	2.8	59
177	Arginase in glomerulonephritis. Kidney International, 2002, 61, 876-881.	5.2	16
178	Arginase in Glomerulonephritis. Nephron Experimental Nephrology, 2000, 8, 128-134.	2.2	11
179	Induced nitric oxide (NO) synthesis in heterologous nephrotoxic nephritis; effects of selective inhibition in neutrophil-dependent glomerulonephritis. Clinical and Experimental Immunology, 1999, 118, 309-314.	2.6	13
180	Inducible Nitric Oxide Synthase Induction in Thy 1 Glomerulonephritis Is Complement and Reactive Oxygen Species Dependent. Nephron Experimental Nephrology, 1999, 7, 26-34.	2.2	27

#	Article	IF	Citations
181	Anti-GBM glomerulonephritis in mice lacking nitric oxide synthase type 2 Rapid Communication. Kidney International, 1998, 53, 932-936.	5.2	33
182	Arginase AI Is Upregulated in Acute Immune Complex-Induced Inflammation. Biochemical and Biophysical Research Communications, 1998, 247, 84-87.	2.1	39
183	L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Kidney International, 1996, 49, 1090-1096.	5.2	47
184	Non-invasive somatotransgenic bioimaging in living animals. F1000Research, 0, 9, 1216.	1.6	1